Carlo Russo
Chief Tech/Sci/R&D Officer chez GENENTA SCIENCE S.P.A.
Fortune : 2 M $ au 31/03/2024
Profil
Carlo Russo is currently the Chief Medical Officer & Head-Development at Genenta Science SpA since 2021.
Prior to this, he was the President & CEO at VaxInnate Corp.
He also served as the Chief Medical Officer & Executive Vice President at Adverum Biotechnologies, Inc. in 2016.
Dr. Russo holds a doctorate degree from the University of Genoa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENENTA SCIENCE SPA
3,28% | 19/04/2023 | 598 417 ( 3,28% ) | 2 M $ | 31/03/2024 |
Postes actifs de Carlo Russo
| Sociétés | Poste | Début |
|---|---|---|
| GENENTA SCIENCE S.P.A. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Anciens postes connus de Carlo Russo
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01/07/2016 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Chief Executive Officer | - |
Formation de Carlo Russo
| University of Genoa | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| GENENTA SCIENCE S.P.A. | Health Technology |
| Entreprise privées | 1 |
|---|---|
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
